ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

4:00PM-5:30PM: Abstract Number: 1679

Effects of Janus Kinase Inhibitor on TNF-a and IL-6-Induced Osteoclasts and RANKL-Induced Osteoclasts in Peripheral Blood Monocytes from Patients with Rheumatoid Arthritis

Abstracts: RA – Treatments II: RA Treatment Safety

4:00PM-5:30PM: Abstract Number: 1665

Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science

4:00PM-5:30PM: Abstract Number: 1704

Esophageal Mucosal Erosions Can Predict the Deterioration of Lung Function over a Four-year Follow-up Period and Long-term Mortality in Patients with Interstitial Lung Disease Associated with Scleroderma

Abstracts: Systemic Sclerosis & Related Disorders II: Clinical Research

4:00PM-5:30PM: Abstract Number: 1670

Exacerbation of Immune-mediated Inflammatory Diseases in COVID19 Sequelae

Abstracts: Infection-related Rheumatic Disease

4:00PM-5:30PM: Abstract Number: 1664

Fibroblast Specific Interferon Regulatory Factor 7 (IRF7) Expression Is a Key Link Between Type I Interferon Activation and the Exaggerated Dermal and Pulmonary Fibrosis in Systemic Sclerosis

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science

4:00PM-5:30PM: Abstract Number: 1669

High Incidence of Immune-mediated Inflammatory Diseases in Sepsis Survivors: A Nationwide Exposed-non-exposed Epidemiological Study

Abstracts: Infection-related Rheumatic Disease

4:00PM-5:30PM: Abstract Number: 1698

High-throughput Proteomics Identities a Spectrum of Novel Serum Biomarkers of Lupus Nephritis

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Omics

4:00PM-5:30PM: Abstract Number: 1673

Immunomodulatory Treatment and Autoimmune Patient Responses to COVID-19 Booster Shots: Results from the Covid-19 VaccinE Response in Rheumatology Patients (COVER) Study

Abstracts: Infection-related Rheumatic Disease

4:00PM-5:30PM: Abstract Number: 1699

Immunosuppression with Targeted Therapies Reduces Morbidity and Mortality in Pre-Capillary Pulmonary Hypertension Associated with Systemic Sclerosis: A EUSTAR Analysis

Abstracts: Systemic Sclerosis & Related Disorders II: Clinical Research

4:00PM-5:30PM: Abstract Number: 1700

Incidence and Risk Factors for New Onset of Interstitial Lung Disease in Systemic Sclerosis: A EUSTAR Analysis

Abstracts: Systemic Sclerosis & Related Disorders II: Clinical Research

4:00PM-5:30PM: Abstract Number: 1703

Increased Mortality and Cardiovascular Events in Male Patients with Systemic Sclerosis: Left Ventricular Global Longitudinal Strain as Possible Screening Tool

Abstracts: Systemic Sclerosis & Related Disorders II: Clinical Research

4:00PM-5:30PM: Abstract Number: 1692

Insights on the Use of JAK-inhibitors in Patients with Psoriatic Arthritis in an International Collaboration of Registers (the “JAK-pot” Study)

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA

4:00PM-5:30PM: Abstract Number: 1688

Izokibep Demonstrates Major Disease Control on ACR70, PASI100 and Enthesitis Resolution in Patients with Active Psoriatic Arthritis Treated Through 46 Weeks

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA

4:00PM-5:30PM: Abstract Number: 1657

Mapping the Network of Coordinated Immune Dysregulation in Juvenile Dermatomyositis at Single-cell Resolution

Abstracts: Pediatric Rheumatology – Basic Science

4:00PM-5:30PM: Abstract Number: 1697

Molecular Characterisation of Remission and Lupus Low Disease Activity State (LLDAS) by Whole-Blood Transcriptome-Based Pathways in a Pan-European Systemic Lupus Erythematosus Cohort

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Omics

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].